Acquiring Company
Halozyme Therapeutics
Acquired Company
Surf Bio
San DiegoPalo AltoManufacturingBiotechnologyHealth CarePharmaceuticalBiopharmaBiotechnologyHealth CareScience And EngineeringDescription
Halozyme Therapeutics, Inc. announced the acquisition of Surf Bio, Inc. for an upfront payment of $300 million, with potential milestone payments of up to $100 million. This acquisition aims to enhance Halozyme's drug delivery capabilities through Surf Bio's innovative hyperconcentration technology. The deal was finalized in December 2025 and supports Halozyme's long-term growth strategy.
Quick answer
Halozyme Therapeutics is acquiring Surf Bio for $300 million, announced January 28, 2026. Halozyme Therapeutics is based in San Diego, California, United States.
- How much did Halozyme Therapeutics pay for Surf Bio?
- The reported deal value is $300 million.
- What does Halozyme Therapeutics do?
- Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.
- Where are Halozyme Therapeutics and Surf Bio based?
- Halozyme Therapeutics is based in San Diego, California, United States. Surf Bio is based in Palo Alto, California, United States.
- Who are the decision-makers at Halozyme Therapeutics?
- Fundz holds 3 contacts at Halozyme Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical and Biopharma
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Kopran Limited to merge with Kopran Laboratories Limited (February 27, 2026)
- GSK to acquire 35Pharma for HS235 development (February 25, 2026)
- AbbVie to acquire Revolution Medicines soon (January 9, 2026)
- Servier Pharmaceuticals to acquire Day One Biopharma (March 11, 2026)
- Halozyme to acquire Hypercon for biotech expansion (March 4, 2026)
- Alkermes acquires Avadel Pharmaceuticals for growth (February 25, 2026)
Who to call at Halozyme Therapeutics, and when
When Halozyme Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Halozyme Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Halozyme Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Halozyme Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Halozyme Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Surf Bio?
Surf Bio was acquired by Halozyme Therapeutics, based in San Diego. The deal was reported on January 28, 2026. Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. Halozyme Therapeutics is publicly traded (HALO) and operates in Manufacturing.
When did Halozyme Therapeutics acquire Surf Bio?
Halozyme Therapeutics's acquisition of Surf Bio was reported on January 28, 2026. Halozyme Therapeutics, Inc. announced the acquisition of Surf Bio, Inc. for an upfront payment of $300 million, with potential milestone payments of up to $100 million. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Surf Bio do?
Surf Bio is a preclinical biopharmaceutical company leveraging a novel biotechnology platform to develop enhanced therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other therapeutic areas. It is privately held, operating in Biotechnology, and is based in Palo Alto.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.